Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct;25(10):1283-1288.
doi: 10.1007/s11864-024-01265-6. Epub 2024 Oct 2.

The Role of SIRT1 in Leukemia

Zhongqi Wu #  1   2 , Tianxin Lyu #  3 , Leizhen Wu  4 , Hui Yang  5 , Wenqiang Li  6   7
Affiliations
Review

The Role of SIRT1 in Leukemia

Zhongqi Wu et al. Curr Treat Options Oncol. 2024 Oct.

Abstract

Leukemia is a type of hematological malignancy (HM) caused by uncontrolled proliferation, apoptosis, and differentiation of hematopoietic stem cells (HSCs). Leukemia cells proliferate greatly in the bone marrow (BM), infiltrate other tissues and organs, and affect the normal hematopoietic function. Although the emergence of new targeted agents and immune agents has improved the prognosis of patients, due to the complex pathogenic factors and heterogeneity of leukemia, there are still some patients with poor prognosis. Recent studies have shown that silent information regulator 1 (SIRT1) is involved in the proliferation, apoptosis, metabolism, and senescence of leukemia cells. As a double-edged sword in leukemia cells, SIRT1 can both promote and inhibit the growth of leukemia cells. Since its mechanism of action has not been elucidated, it is urgent to explore the regulatory mechanism of SIRT1 in leukemia. In this review, we discussed the mechanisms of SIRT1 in different aspects of leukemia, providing a theoretical basis for the treatment of patients with leukemia.

Keywords: Autophagy; DNA damage repair; Leukemia; SIRT1.

PubMed Disclaimer

References

References and Recommended Reading

    1. Fajardo-Orduña GR, et al. Role of SIRT1 in chemoresistant leukemia. Int J Mol Sci. 2023;24(19):14470. https://doi.org/10.3390/ijms241914470 . - DOI - PubMed - PMC
    1. Döhner H, et al. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–52. https://doi.org/10.1056/NEJMra1406184 . - DOI - PubMed
    1. Lancho O, et al. A therapeutically targetable NOTCH1–SIRT1–KAT7 axis in T-cell leukemia. Blood Cancer Discov. 2023;4(1):12–33. https://doi.org/10.1158/2643-3230.BCD-22-0098 . - DOI - PubMed
    1. Vachharajani V, McCall CE. Sirtuins: potential therapeutic targets for regulating acute inflammatory response? Expert Opin Ther Targets. 2020;24(5):489–97. https://doi.org/10.1080/14728222.2020.1743268 . - DOI - PubMed - PMC
    1. Cai H, et al. Discovery of novel SIRT1/2 inhibitors with effective cytotoxicity against human leukemia cells. J Chem Inf Model. 2023;63(15):4780–90. https://doi.org/10.1021/acs.jcim.3c00556 . - DOI - PubMed

LinkOut - more resources